271 related articles for article (PubMed ID: 18836592)
41. [Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
Rubio-San-Simón A; Lázaro Rodríguez I; Vázquez Gómez F; Vivanco Martínez JL; Pérez Alonso V
An Pediatr (Engl Ed); 2019 Apr; 90(4):246-247. PubMed ID: 29798814
[No Abstract] [Full Text] [Related]
42. Eltrombopag reduces bleeding complications and the need of platelet transfusions in cirrhotic thrombocytopenic patients subjected to invasive procedures.
Castelli R; Gidaro A; Lambertenghi Deliliers G
Blood Coagul Fibrinolysis; 2021 Mar; 32(2):163-166. PubMed ID: 33555693
[No Abstract] [Full Text] [Related]
43. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
Trautmann K; Jakob C; von Grünhagen U; Schleyer E; Brümmendorf TH; Siegert G; Ehninger G; Platzbecker U
Thromb Haemost; 2012 Aug; 108(2):397-8. PubMed ID: 22739569
[No Abstract] [Full Text] [Related]
44. Stable Liver Function during Long-Term Administration of Eltrombopag, a Thrombopoietin Receptor Agonist, in Patients with Chronic Liver Disease.
Kurokawa T; Murata S; Ohkohchi N
Tohoku J Exp Med; 2016 Dec; 240(4):277-279. PubMed ID: 27928110
[TBL] [Abstract][Full Text] [Related]
45. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
[TBL] [Abstract][Full Text] [Related]
46. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
[No Abstract] [Full Text] [Related]
47. A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag.
Suzuki N; Hiraga J; Hariyama Y; Takagi Y; Ohashi H; Kishigami Y; Oguchi H; Kagami Y
Int J Hematol; 2018 Jul; 108(1):109-111. PubMed ID: 29188582
[TBL] [Abstract][Full Text] [Related]
48. Does eltrombopag really ENABLE SVR?
Leber A; Feld JJ
Gastroenterology; 2014 Feb; 146(2):339-42. PubMed ID: 24361434
[No Abstract] [Full Text] [Related]
49. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
Kellum A; Jagiello-Gruszfeld A; Bondarenko IN; Patwardhan R; Messam C; Mostafa Kamel Y
Curr Med Res Opin; 2010 Oct; 26(10):2339-46. PubMed ID: 20735290
[TBL] [Abstract][Full Text] [Related]
50. Usage of eltrombopag for chronic immune thrombocytopenia as a pretreatment for splenectomy.
Uwagawa T; Misawa T; Furukawa K; Ito R; Futagawa Y; Yahagi Y; Aiba K; Yanaga K
Acta Haematol; 2013; 129(1):45-7. PubMed ID: 23128016
[No Abstract] [Full Text] [Related]
51. Eltrombopag for thrombocytopenic patients with chronic HCV infection.
Maan R; Veldt BJ; Janssen HL
Gastroenterology; 2014 Jul; 147(1):254-5. PubMed ID: 24877871
[No Abstract] [Full Text] [Related]
52. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
Modi Y; Shaaban H; Gauchan D; Maroules M
J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
[TBL] [Abstract][Full Text] [Related]
53. Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.
Au WY; Ma ES; Chow PC; Kan YT
Ann Hematol; 2014 May; 93(5):881-2. PubMed ID: 24048635
[No Abstract] [Full Text] [Related]
54. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia.
Favier R; Feriel J; Favier M; Denoyelle F; Martignetti JA
Pediatrics; 2013 Sep; 132(3):e793-5. PubMed ID: 23940247
[TBL] [Abstract][Full Text] [Related]
55. Eltrombopag for thrombocytopenic patients with hepatitis C virus infection and cirrhosis.
Ji F; Deng H; Li Z
Gastroenterology; 2014 Jul; 147(1):253-4. PubMed ID: 24877867
[No Abstract] [Full Text] [Related]
56. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375
[TBL] [Abstract][Full Text] [Related]
57. Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial.
Arnold DM; Heddle NM; Cook RJ; Hsia C; Blostein M; Jamula E; Sholzberg M; Lin Y; Kassis J; Larratt L; Tinmouth A; Amini S; Schipperus M; Lim W; Vishnu P; Warner M; Carruthers J; Li N; Lane S; Kelton JG
Lancet Haematol; 2020 Sep; 7(9):e640-e648. PubMed ID: 32853584
[TBL] [Abstract][Full Text] [Related]
58. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Fattizzo B; Levati G; Cassin R; Barcellini W
Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
[TBL] [Abstract][Full Text] [Related]
59. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.
Katsutani S; Tomiyama Y; Kimura A; Miyakawa Y; Okamoto S; Okoshi Y; Ninomiya H; Kosugi H; Ishii K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
Int J Hematol; 2013 Sep; 98(3):323-30. PubMed ID: 23896965
[TBL] [Abstract][Full Text] [Related]
60. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]